{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:15:26Z","timestamp":1774260926124,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10147-023-02385-z","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T11:02:22Z","timestamp":1688814142000},"page":"1343-1353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis"],"prefix":"10.1007","volume":"28","author":[{"given":"Keisuke","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"key":"2385_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","volume":"4","author":"J Dine","year":"2017","unstructured":"Dine J, Gordon R, Shames Y et al (2017) Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs 4:127\u2013135","journal-title":"Asia Pac J Oncol Nurs"},{"key":"2385_CR2","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2019) Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol 5:1411\u20131420","journal-title":"JAMA Oncol"},{"key":"2385_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jemermed.2018.07.005","volume":"55","author":"AT Hryniewicki","year":"2018","unstructured":"Hryniewicki AT, Wang C, Shatsky RA et al (2018) Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians. J Emerg Med 55:489\u2013502","journal-title":"J Emerg Med"},{"key":"2385_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/onco.13740","volume":"26","author":"GE Molina","year":"2021","unstructured":"Molina GE, Zubiri L, Cohen JV et al (2021) Temporal trends and outcomes among patients admitted for immune-related adverse events: a single-center retrospective cohort study from 2011 to 2018. Oncologist 26:514\u2013522","journal-title":"Oncologist"},{"key":"2385_CR5","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) National Comprehensive Cancer Network, Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768","journal-title":"J Clin Oncol"},{"key":"2385_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson JA, Schneider BJ, Brahmer J et al (2020) NCCN guidelines insights: management of immunotherapy-related toxicities, Version 1.2020. J Natl Compr Canc Netw 18:230\u2013241","journal-title":"J Natl Compr Canc Netw"},{"key":"2385_CR7","doi-asserted-by":"publisher","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","volume":"8","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Tucci M, Adamo V et al (2020) Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer 8:e001361","journal-title":"J Immunother Cancer"},{"key":"2385_CR8","doi-asserted-by":"publisher","first-page":"e0263247","DOI":"10.1371\/journal.pone.0263247","volume":"17","author":"K Takada","year":"2022","unstructured":"Takada K, Shimokawa M, Takamori S et al (2022) The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors. PLoS ONE 17:e0263247","journal-title":"PLoS ONE"},{"key":"2385_CR9","doi-asserted-by":"publisher","first-page":"346.e1","DOI":"10.1016\/j.urolonc.2022.02.020","volume":"40","author":"W Fukuokaya","year":"2022","unstructured":"Fukuokaya W, Kimura T, Komura K et al (2022) Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors. Urol Oncol 40:346.e1-346.e8","journal-title":"Urol Oncol"},{"key":"2385_CR10","doi-asserted-by":"publisher","first-page":"716317","DOI":"10.3389\/fimmu.2021.716317","volume":"12","author":"Q Giordan","year":"2021","unstructured":"Giordan Q, Salleron J, Vallance C et al (2021) Impact of antibiotics and proton pump inhibitors on efficacy and tolerance of anti-PD-1 immune checkpoint inhibitors. Front Immunol 12:716317","journal-title":"Front Immunol"},{"key":"2385_CR11","first-page":"1311","volume":"68","author":"JJ Heidelbaugh","year":"2003","unstructured":"Heidelbaugh JJ, Nostrant TT, Kim C et al (2003) Management of gastroesophageal reflux disease. Am Fam Phys 68:1311\u20131318","journal-title":"Am Fam Phys"},{"key":"2385_CR12","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1021\/mp400403s","volume":"10","author":"GS Smelick","year":"2013","unstructured":"Smelick GS, Heffron TP, Chu L et al (2013) Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm 10:4055\u20134062","journal-title":"Mol Pharm"},{"key":"2385_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","volume":"168","author":"N Inatomi","year":"2016","unstructured":"Inatomi N, Matsukawa J, Sakurai Y et al (2016) Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther 168:12\u201322","journal-title":"Pharmacol Ther"},{"key":"2385_CR14","doi-asserted-by":"publisher","first-page":"1929727","DOI":"10.1080\/2162402X.2021.1929727","volume":"10","author":"BD Qin","year":"2021","unstructured":"Qin BD, Jiao XD, Zhou XC et al (2021) Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer. Oncoimmunology 10:1929727","journal-title":"Oncoimmunology"},{"key":"2385_CR15","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1111\/bcp.15276","volume":"88","author":"N Wei","year":"2022","unstructured":"Wei N, Zheng B, Que W et al (2022) The association between proton pump inhibitor use and systemic anti-tumour therapy on survival outcomes in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 88:3052\u20133063","journal-title":"Br J Clin Pharmacol"},{"key":"2385_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"2385_CR17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088\u20131101","journal-title":"Biometrics"},{"key":"2385_CR18","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) PRISMA Group, preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"2385_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2020.09.033","volume":"142","author":"S Buti","year":"2021","unstructured":"Buti S, Bersanelli M, Perrone F et al (2021) Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. Eur J Cancer 142:18\u201328","journal-title":"Eur J Cancer"},{"key":"2385_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31:435\u2013446","journal-title":"J Am Soc Nephrol"},{"key":"2385_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/CMR.0000000000000299","volume":"26","author":"JJ Failing","year":"2016","unstructured":"Failing JJ, Finnes HD, Kottschade LA et al (2016) Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Res 26:609\u2013615","journal-title":"Melanoma Res"},{"key":"2385_CR22","doi-asserted-by":"publisher","first-page":"175883592110005","DOI":"10.1177\/17588359211000591","volume":"13","author":"L Gaucher","year":"2021","unstructured":"Gaucher L, Adda L, S\u00e9journ\u00e9 A et al (2021) Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol 13:17588359211000592","journal-title":"Ther Adv Med Oncol"},{"key":"2385_CR23","doi-asserted-by":"publisher","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","volume":"9","author":"S Gupta","year":"2021","unstructured":"Gupta S, Short SAP, Sise ME et al (2021) ICPi-AKI Consortium Investigators, acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer 9:e003467","journal-title":"J Immunother Cancer"},{"key":"2385_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41416-021-01606-4","volume":"126","author":"AM Hopkins","year":"2022","unstructured":"Hopkins AM, Kichenadasse G, McKinnon RA et al (2022) Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer 126:42\u201347","journal-title":"Br J Cancer"},{"key":"2385_CR25","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s12094-019-02282-w","volume":"22","author":"A Iglesias-Santamar\u00eda","year":"2020","unstructured":"Iglesias-Santamar\u00eda A (2020) Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer. Clin Transl Oncol 22:1481\u20131490","journal-title":"Clin Transl Oncol"},{"key":"2385_CR26","doi-asserted-by":"publisher","first-page":"175883592110109","DOI":"10.1177\/17588359211010937","volume":"13","author":"T Jun","year":"2021","unstructured":"Jun T, Ozbek U, Dharmapuri S et al (2021) Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol 13:17588359211010936","journal-title":"Ther Adv Med Oncol"},{"key":"2385_CR27","doi-asserted-by":"publisher","first-page":"e0252978","DOI":"10.1371\/journal.pone.0252978","volume":"16","author":"MS Koks","year":"2021","unstructured":"Koks MS, Ocak G, Suelmann BBM et al (2021) Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study. PLoS ONE 16:e0252978","journal-title":"PLoS ONE"},{"key":"2385_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","volume":"157","author":"M Kostine","year":"2021","unstructured":"Kostine M, Mauric E, Tison A et al (2021) Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer 157:474\u2013484","journal-title":"Eur J Cancer"},{"key":"2385_CR29","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1111\/1759-7714.14001","volume":"12","author":"K Miura","year":"2021","unstructured":"Miura K, Sano Y, Niho S et al (2021) Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective study. Thorac Cancer 12:1983\u20131994","journal-title":"Thorac Cancer"},{"key":"2385_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11523-021-00861-y","volume":"17","author":"V Mollica","year":"2022","unstructured":"Mollica V, Santoni M, Matrana MR et al (2022) Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma. Target Oncol 17:61\u201368","journal-title":"Target Oncol"},{"key":"2385_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/10600280211033938","volume":"56","author":"K Peng","year":"2022","unstructured":"Peng K, Chen K, Teply BA et al (2022) Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients. Ann Pharmacother 56:377\u2013386","journal-title":"Ann Pharmacother"},{"key":"2385_CR32","doi-asserted-by":"publisher","first-page":"100090","DOI":"10.1016\/j.esmoop.2021.100090","volume":"6","author":"J Ruiz-Ba\u00f1obre","year":"2021","unstructured":"Ruiz-Ba\u00f1obre J, Molina-D\u00edaz A, Fern\u00e1ndez-Calvo O et al (2021) Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study. ESMO Open 6:100090","journal-title":"ESMO Open"},{"key":"2385_CR33","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","volume":"14","author":"H Seethapathy","year":"2019","unstructured":"Seethapathy H, Zhao S, Chute DF et al (2019) The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14:1692\u20131700","journal-title":"Clin J Am Soc Nephrol"},{"key":"2385_CR34","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/ndt\/gfaa137","volume":"36","author":"C Stein","year":"2021","unstructured":"Stein C, Burtey S, Mancini J et al (2021) Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrol Dial Transplant 36:1664\u20131674","journal-title":"Nephrol Dial Transplant"},{"key":"2385_CR35","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.21873\/anticanres.15638","volume":"42","author":"I Tomisaki","year":"2022","unstructured":"Tomisaki I, Harada M, Minato A et al (2022) Impact of the use of proton pump inhibitors on pembrolizumab effectiveness for advanced urothelial carcinoma. Anticancer Res 42:1629\u20131634","journal-title":"Anticancer Res"},{"key":"2385_CR36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clgc.2022.01.017","volume":"20","author":"J Yin","year":"2022","unstructured":"Yin J, Elias R, Peng L et al (2022) Chronic use of proton pump inhibitors is associated with an increased risk of immune checkpoint inhibitor colitis in renal cell carcinoma. Clin Genitourin Cancer 20:260\u2013269","journal-title":"Clin Genitourin Cancer"},{"key":"2385_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.lungcan.2019.01.017","volume":"130","author":"S Zhao","year":"2019","unstructured":"Zhao S, Gao G, Li W et al (2019) Antibiotics are associated with attenuated efficacy of anti-PD-1\/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer 130:10\u201317","journal-title":"Lung Cancer"},{"key":"2385_CR38","doi-asserted-by":"publisher","first-page":"798272","DOI":"10.3389\/fphar.2022.798272","volume":"13","author":"M Bridoux","year":"2022","unstructured":"Bridoux M, Simon N, Turpin A (2022) Proton pump inhibitors and cancer: current state of play. Front Pharmacol 13:798272","journal-title":"Front Pharmacol"},{"key":"2385_CR39","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann F, Bonder MJ, Vila AV et al (2016) Proton pump inhibitors affect the gut microbiome. Gut 65:740\u2013748","journal-title":"Gut"},{"key":"2385_CR40","doi-asserted-by":"publisher","first-page":"e22058","DOI":"10.4161\/onci.22058","volume":"2","author":"M Bellone","year":"2013","unstructured":"Bellone M, Calcinotto A, Filipazzi P et al (2013) The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors. Oncoimmunology 2:e22058","journal-title":"Oncoimmunology"},{"key":"2385_CR41","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.surg.2011.07.067","volume":"150","author":"LN Diebel","year":"2011","unstructured":"Diebel LN, Liberati DM, Hall-Zimmerman L (2011) H2 blockers decrease gut mucus production and lead to barrier dysfunction in vitro. Surgery 150:736\u2013743","journal-title":"Surgery"},{"key":"2385_CR42","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90:638\u2013647","journal-title":"Kidney Int"},{"key":"2385_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41581-018-0035-1","volume":"14","author":"K Sury","year":"2018","unstructured":"Sury K, Perazella MA, Shirali AC (2018) Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol 14:571\u2013588","journal-title":"Nat Rev Nephrol"},{"key":"2385_CR44","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer. JAMA Oncol 4:374\u2013378","journal-title":"JAMA Oncol"},{"key":"2385_CR45","doi-asserted-by":"publisher","first-page":"e59125","DOI":"10.1172\/jci.insight.59125","volume":"3","author":"A Osa","year":"2018","unstructured":"Osa A, Uenami T, Koyama S et al (2018) Clinical implications of monitoring nivolumab immunokinetics in non\u2013small cell lung cancer patients. JCI Insight 3:e59125","journal-title":"JCI Insight"},{"key":"2385_CR46","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamaoncol.2017.5236","volume":"4","author":"G Ritchie","year":"2018","unstructured":"Ritchie G, Gasper H, Man J et al (2018) Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis. JAMA Oncol 4:522\u2013528","journal-title":"JAMA Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02385-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T05:09:21Z","timestamp":1695964161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02385-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2385"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02385-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,8]]},"assertion":[{"value":"15 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}